Treatment with tumour necrosis factor inhibitors is not associated with a significantly increased risk of recurrent cancer among patients with rheumatoid arthritis, researchers report.
Short-term induction therapy with a tumor necrosis factor inhibitor plus methotrexate could alter disease development in some patients with early rheumatoid arthritis, providing long-term benefit, results of the DINORA trial suggest.
Results of a phase III trial indicate that both the immediate and extended release formulations of febuxostat reduce serum uric acid levels in patients with gout, including those with impaired renal function.
Collaboration between rheumatologists and dermatologists in a combined clinic may help improve outcomes for patients with psoriatic arthritis, study results suggest.
Follow medwireNews